300
Participants
Start Date
December 31, 2002
Study Completion Date
January 31, 2004
sildenafil
In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
placebo
In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
sildenafil
Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
Pfizer Investigational Site, Buffalo
Pfizer Investigational Site, Baltimore
Pfizer Investigational Site, Baltimore
Pfizer Investigational Site, Huntsville
Pfizer Investigational Site, New Albany
Pfizer Investigational Site, Minneapolis
Pfizer Investigational Site, St Louis
Pfizer Investigational Site, Richmond Heights
Pfizer Investigational Site, Overland Park
Pfizer Investigational Site, New Orleans
Pfizer Investigational Site, San Antonio
Pfizer Investigational Site, Phoenix
Pfizer Investigational Site, Los Angeles
Pfizer Investigational Site, Beverly Hills
Pfizer Investigational Site, Duarte
Pfizer Investigational Site, La Jolla
Pfizer Investigational Site, La Jolla
Pfizer Investigational Site, San Diego
Pfizer Investigational Site, Laguna Woods
Pfizer Investigational Site, Portland
Pfizer Investigational Site, Medford
Pfizer Investigational Site, Tacoma
Pfizer Investigational Site, Kirkland
Pfizer Investigational Site, Tacoma
Pfizer Investigational Site, Norwalk
Pfizer Investigational Site, Waterbury
Pfizer Investigational Site, Boston
Pfizer Investigational Site, San Antonio
Pfizer Investigational Site, Calgary
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY